Lifeboat Foundation

Scientists are able to use brain tests on three-year-olds to determine which children are more likely to grow up to become criminals. It sounds like Minority Report come to life: An uncomfortable idea presenting myriad ethical concerns. But, though unnerving, the research is nuanced and could potentially be put to good use.

In the study, published in Nature Human Behavior this week, researchers led by neuroscientists at Duke University showed that those with the lowest 20% brain health results aged three went on to commit more than 80% of crimes as adults. The research used data from a New Zealand longitudinal study of more than 1,000 people from birth in the early 1970s until they reached 38 years old. This distribution, of 20% of a population accounting for 80% of an effect, is strong but not unusual. In fact, it follows the “Pareto principle.” The authors write in their paper:

In Pareto’s day, the problem definition was that 20% of families owned 80% of land in Italy. The so-called Pareto principle is alive and useful today: for example, in software engineering, 20% of the code is said to contain 80% of the errors.

Continue reading “The disturbingly accurate brain science that identifies potential criminals while they’re still toddlers” »

Biologist Daisy Robinton talks about engineering aging and the possibilities new technology offers.

Harvard University biologist Daisy Robinton reveals how science is helping us understand how and why we age.

Continue reading “Can we engineer the end of ageing?” »

Check out the LEAF interview with Synthetic Biology company CellAge who plan to use their technology to create aging biomarkers for the research community to use for free as well as new approaches to removing senescent cells.

CellAge are using synthetic biology to remove senescent cells that accumulate with age and contribute to disease. We took the time to interview them about their technology, treating age-related diseases and their plans for the future.

You can also check out their campaign on Lifespan.io:

Continue reading “CellAge – Synthetic biology meets senolytics” »

What combinations of mutations help cancer cells survive? Which cells in the brain are involved in the onset of Alzheimer’s? How do immune cells conduct their convoluted decision-making processes? Researchers at the Weizmann Institute of Science have now combined two powerful research tools — CRISPR gene editing and single cell genomic profiling — in a method that may finally help us get answers to these questions and many more.

The new technology enables researchers to manipulate gene functions within single cells, and understand the results of each change in extremely high resolution. A single experiment with this method, say the scientists, may be equal to thousands of experiments conducted using previous approaches, and it may advance the field of genetic engineering for medical applications.

The gene-editing technique CRISPR is already transforming biology research around the world, and its clinical use in humans is just around the corner. CRISPR was first discovered in bacteria as a primitive acquired immune system, which cuts and pastes viral DNA into their own genomes to fight viruses. In recent years, this bacterial system has been adopted by researchers to snip out or insert nearly any gene in any organism or cell, quickly and efficiently. “But CRISPR, on its own, is a blunt research tool, since we often have trouble observing or understanding the outcome of this genomic editing,” says Prof. Ido Amit of the Weizmann Institute of Science’s Immunology Department, who led the study. “Most studies so far have looked for black-or-white types of effects,” adds Dr. Diego Jaitin, of Amit’s lab group, “but the majority of processes in the body are complex and even chaotic.”

Excellent article by Nick Gillespie, Editor-in Chief of Reason. Genetic editing is so far the 21st Century’s most important science—and it’s already being challenged by many as too radical: http://reason.com/blog/2016/12/15/will-gene-editing-technologies-spark-the #transhumanism #CRISPR #Future

The folks behind CRISPR gene editing were runners-up for Time’s Person of the Year. Their creation may win the future for secular China.

Continue reading “Will Gene-Editing Technologies Spark the Next Cold War? They Already Have” »

Synthetic biology meets senolytics at Lifespan.io

We are developing tools to help researchers accurately target and remove dysfunctional cells in the body that have entered a state called “senescence”, and thereby assist in restoring it to youthful functionality. Please subscribe, share, and fund our campaign today! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe: https://www.youtube.com/user/LifespanIO?sub_confirmation=1

Continue reading “CellAge: Senescent Cell Targeting Technology Video” »

Dr. Aubrey de Grey from the SENS Research Foundation was kind enough to talk in support of CellAge and their campaign on Lifespan.io

We are developing tools to help researchers accurately target and remove dysfunctional cells in the body that have entered a state called “senescence”, and thereby assist in restoring it to youthful functionality. Please subscribe, share, and fund our campaign today! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe: https://www.youtube.com/user/LifespanIO?sub_confirmation=1

Continue reading “CellAge: Dr. Aubrey de Grey Endorsement Video” »

Excellent. Now, the question is “has Microsoft seen this?” as they are working on solving Diabetes too as part of their Synbio program that has already shown us their DNA Data Storage.

People with type 1 diabetes must inject themselves with insulin multiple times per day. This is because their immune system has destroyed cells in the pancreas that secrete insulin to maintain a healthy blood glucose level.

A team of bioengineers now report a possible alternative to such injections. The researchers engineered human kidney cells to act like pancreatic β cells, namely to sense blood glucose levels and produce insulin accordingly (Science 2016, DOI: 10.1126/science.aaf4006). When implanted in mice with type 1 diabetes, the cells prevent high blood glucose levels, also known as hyperglycemia.

Continue reading “Potential diabetes therapy: Engineered cells that control blood sugar” »

After getting off its $100 million-plus IPO in the summer, gene editing biotech Intellia Therapeutics is getting ready for human tests of its preclinical CRISPR tech with new digs designed to help bolster its research capabilities.

The biotech, which has the backing and partnerships of the likes of Atlas, Novartis and Regeneron, is on the move as it heads over to its new lab facilities at 40 Erie Street, in Cambridge, MA.

“The field of genome editing is rapidly evolving and our work to develop therapies for patients requires that we have the infrastructure necessary for R&D growth and prepare for preclinical studies and clinical trials,” said Dr. Nessan Bermingham, CEO and founder of Intellia Therapeutics.

Continue reading “Intellia gears up for human testing of CRISPR with new HQ, set to double staffers” »